Sartorius Stedim Biotech (CHIX:DIMP) Beneish M-Score: -2.78 (As of Jun. 24, 2026)


CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €162.10
GF Value €207.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Beneish M-Score?

Sartorius Stedim Biotech CHIX:DIMP 84 Beneish M-Score is -2.78 as of Jun. 24, 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 66.8% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sartorius Stedim Biotech's Beneish M-Score or its related term are showing as below:

CHIX:DIMp' s Beneish M-Score Range Over the Past 10 Years
Min: -3.03   Med: -2.51   Max: -1.39
Current: -2.78

During the past 13 years, the highest Beneish M-Score of Sartorius Stedim Biotech was -1.39. The lowest was -3.03. And the median was -2.51.


Sartorius Stedim Biotech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Beneish M-Score Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.51 -2.01 -2.95 -2.89 -2.95

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.03 -2.97 -2.92 -2.95 -2.78

CHIX:DIMP vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Beneish M-Score falls into.


CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sartorius Stedim Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9339+0.528 * 0.9816+0.404 * 0.9936+0.892 * 1.0443+0.115 * 1.0121
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.963+4.679 * -0.060759-0.327 * 0.9636
=-2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €260 Mil.
Revenue was 761.5 + 772.2 + 705.7 + 745 = €2,984 Mil.
Gross Profit was 345.4 + 316.9 + 327.4 + 344.7 = €1,334 Mil.
Total Current Assets was €1,651 Mil.
Total Assets was €8,190 Mil.
Property, Plant and Equipment(Net PPE) was €2,034 Mil.
Depreciation, Depletion and Amortization(DDA) was €322 Mil.
Selling, General, & Admin. Expense(SGA) was €658 Mil.
Total Current Liabilities was €1,609 Mil.
Long-Term Debt & Capital Lease Obligation was €2,009 Mil.
Net Income was 88.1 + 47.3 + 64.2 + 68.5 = €268 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was 193.3 + 246.5 + 201 + 124.9 = €766 Mil.
Total Receivables was €267 Mil.
Revenue was 744.6 + 751.3 + 655.4 + 706.4 = €2,858 Mil.
Gross Profit was 356.3 + 316.3 + 275.5 + 306.2 = €1,254 Mil.
Total Current Assets was €1,780 Mil.
Total Assets was €8,304 Mil.
Property, Plant and Equipment(Net PPE) was €1,927 Mil.
Depreciation, Depletion and Amortization(DDA) was €309 Mil.
Selling, General, & Admin. Expense(SGA) was €655 Mil.
Total Current Liabilities was €965 Mil.
Long-Term Debt & Capital Lease Obligation was €2,842 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(260.4 / 2984.4) / (267 / 2857.7)
=0.087254 / 0.093432
=0.9339

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1254.3 / 2857.7) / (1334.4 / 2984.4)
=0.438919 / 0.447125
=0.9816

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1650.7 + 2034.3) / 8189.8) / (1 - (1780 + 1926.9) / 8303.5)
=0.55005 / 0.553574
=0.9936

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2984.4 / 2857.7
=1.0443

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(309.1 / (309.1 + 1926.9)) / (321.8 / (321.8 + 2034.3))
=0.138238 / 0.136582
=1.0121

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(658.2 / 2984.4) / (654.5 / 2857.7)
=0.220547 / 0.22903
=0.963

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2008.9 + 1609.2) / 8189.8) / ((2842.3 + 964.7) / 8303.5)
=0.441781 / 0.458481
=0.9636

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(268.1 - 0 - 765.7) / 8189.8
=-0.060759

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sartorius Stedim Biotech has a M-score of -2.78 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.78 mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Beneish M-Score of -2.78 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #254 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Sartorius Stedim Biotech's Beneish M-Score too high?
Sartorius Stedim Biotech's current Beneish M-Score is -2.78. Based on the distribution chart, Sartorius Stedim Biotech ranks #254 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #254 out of 765 companies for Beneish M-Score. This puts Sartorius Stedim Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Beneish M-Score is -2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.88, compared to a current price of €162.10 — trading 22% below its estimated fair value. The current Beneish M-Score is -2.78. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Beneish M-Score is -2.78 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €162.10 is trading 22% below its estimated GF Value™ of €207.88. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Beneish M-Score: -2.78
  • GF Value™: €207.88 vs. price of €162.10 (22% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€162.10
Price
€207.88
GF Value